Midazolam

Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4 2026 Company advancing pipeline assets NS003 (Ondansetron for chemotherapy-induced nausea and vomiting) and NS004 (metabolic) toward first-in-human studies expected to start in the second half of 2026, significantly expanding the Company’s intranasal product portfolio into additional high value therapeutic areas Company well funded through planned NS002 pivotal study and potential NDA submission TEL AVIV, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the filing of its annual report on Form 20-F for the year ended December 31, 2025, and provided a business update highlighting recent Phase 2 results for NS002 and upcoming clinical milestones. "With positive Phase 2 data for NS002 and a strong cash position, we believe Nasus is well positioned to deliver on multiple clinical inflection points in 2026," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "Following the compelling topline Phase 2 results of NS002, we are advancing our intranasal epinephrine powder formulation towards a pivotal study planned to initiate in the fourth quarter of this year. The Company is well-funded to complete NS002’s pivotal study and see through a potential NDA filing. In addition, we plan to progress our earlier pipeline assets, Ondansetron for chemotherapy induced nausea and vomiting, and NS004 targeting metabolic disorders, into first-in-human studies in the second half of the year and are also advancing NS005 targeting cardiovascular diseases. We believe our pipeline of innovative intranasal products, leveraging our proprietary powder platform technology, can deliver significant clinical benefits to patients and could unlock substantial value to our shareholders. We are committed to executing on this vision.” Business Update NS002 – Intranasal powder Epinephrine for Anaphylaxis Completed Phase 2 single and repeat dose clinical study , with topline results demonstrating statistically significant improvements in time to therapeutic threshold (T100) and a higher proportion of participants reaching therapeutic epinephrine levels within the first minutes following administration, compared to EpiPen®. The data also demonstrated NS002’s consistent absorption across real-world conditions, including under a nasal allergic challenge designed to simulate anaphylaxis scenarios. Advancing toward pivotal development , with a pivotal clinical study expected to initiate in the fourth quarter of 2026 and a planned readout in the first quarter of 2027, subject to regulatory alignment. The Company believes the positive Phase 2 results support continued development toward a potential NDA submission. Early Pipeline Nasus is advancing its earlier-stage pipeline programs, which leverage the Company’s proprietary intranasal powder platform: NS003 – Ondansetron for chemotherapy-induced nausea and vomiting NS004 – targeting metabolic disorders NS005 – targeting cardiovascular diseases All programs are currently in preclinical development, with first-in-human Phase 1 studies expected to initiate in the second half of 2026 for NS003 and NS004, supporting the continued expansion of the Company’s intranasal product portfolio. Financial Results Cash, Cash Equivalents and Marketable Securities : As of December 31, 2025, Nasus had cash, cash equivalents and marketable securities of $4.3 million, compared with cash and cash equivalents of $0.3million as of December 31, 2024. The increase in cash, cash equivalents and short term deposits was primarily a result of our IPO. Following our $15 private placement, which closed in February 2026, Nasus expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the second quarter of 2027. Research and Development Expenses : Research and development expenses were $2.4 million for the year ended December 31, 2025, compared with $0.3 million for the year ended December 31, 2024. The increase was primarily attributable to expenses paid in connection with the development of NS002. General and Administrative Expenses : General and administrative expenses were $2.7 million for the year ended December 31, 2025, compared with $0.7 million for the year ended December 31, 2024. The increase was mainly due to the company’s transition to a public company. Net Loss : For the year ended December 31, 2025, net loss was $5.9 million compared with a net loss of $1.5 million for the year ended December 31, 2024. The total number of shares outstanding as of December 31, 2025 was 9,015,383. The Company has filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”), which can be accessed on its website at Shareholders may request, free of charge, a hard copy of the Annual Report, which includes the Company’s complete audited consolidated financial statements for the year ended December 31, 2025, by contacting ir@nasuspharma.com . About Nasus Pharma Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit or follow on Twitter (X) or LinkedIn . Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: the timing and results of planned clinical studies, including the NS002 pivotal study, potential regulatory submissions, including a potential NDA, the development and timing of pipeline programs, including NS003, NS004 and NS005, expected clinical and development milestones, expansion of the Company’s product portfolio, and the Company’s financial position and expected cash runway. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Company Contact Nasus Pharma Ltd. info@nasuspharma.com Investor Contact Mike Moyer LifeSci Advisors +1-617-308-4306 mmoyer@lifesciadvisors.com

Fourth Quarter, Full-Year 2025 and Selected Highlights: Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period Full-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024 GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025 Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025 Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024 Cash and cash equivalents of $72.9 million as of December 31, 2025 Full-year 2026 revenue guidance of $350 million to $365 million, including $133 million to $153 million in the first half of 2026 and $203 million to $226 million in the second half of 2026 Full-year 2026 Adjusted EBITDA guidance of $80 million to $100 million A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., March 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the fourth quarter and full-year ended December 31, 2025. The Company also posted its fourth quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com . The Company encourages Harrow stockholders to review these documents, which provide additional details concerning the historical results and future expectations for the business. “Last year was a defining year for Harrow, with revenue up 36% for the year and a record fourth quarter that reflected both accelerating demand and improving operating leverage, especially in terms of generating operating cash flow. Our key products are still in the early stages of launch, and each is gaining significant commercial traction. Seeing VEVYE ® , IHEEZO ® , and TRIESENCE ® all show solid signs of growth at the same time underscores the strength of our strategy and the tenacity of our commercial leadership,” said Mark L. Baum, Chief Executive Officer of Harrow. “As we enter 2026, we are building on that momentum across the business: doubling the VEVYE and TRIESENCE sales teams, expanding IHEEZO into the office-based setting, advancing our development pipeline, and operating with greater alignment as One Harrow. I also believe we are going to provide positive surprises this year (and next) with a few products in our portfolio that haven’t received much attention. With multiple growth drivers gaining traction and a larger commercial footprint coming online, I have increasing confidence in our ability to accelerate performance through 2026, to remain on track toward our goal of over $250 million in quarterly revenue by the end of 2027. And that won’t be the end of the story because beginning in 2028, we intend to further leverage our commercial platform by launching late-stage, large market assets in development, like G-MELT™ (formerly MELT-300), YOCHIL™ (formerly MELT-210), a next generation TRIESENCE pre-filled syringe, and other high impact product candidates in other phases of review. We have a tremendous amount of work ahead of us, but I believe we are making great progress as we transition from an early-stage growth company to a long-term cash-generating commercial powerhouse.” Baum added, “Greater clarity in our financial guidance is an area where we owe it to Harrow stockholders to make improvements. Our new approach, while perhaps more conservative, will focus on greater transparency and structure. Our objective going forward is clear: to meet and beat expectations . Establishing and updating financial guidance around our new framework should help narrow the range of expectations and better align them around levels we are confident we can deliver against.” Fourth Quarter and Full-Year 2025 Financial Results: For the Three Months Ended December 31, For the Year Ended December 31, 2025 2024 2025 2024 Total revenues $ 89,092,000 $ 66,831,000 $ 272,303,000 $ 199,614,000 Gross margin 79 % 79 % 75 % 75 % Net income (loss) 6,626,000 6,777,000 (5,139,000 ) (17,481,000 ) Adjusted EBITDA (1) 24,170,000 22,489,000 61,923,000 40,327,000 Net income (loss) per share: Basic 0.18 0.19 (0.14 ) (0.49 ) Diluted 0.17 0.24 (0.14 ) (0.49 ) (1) Adjusted EBITDA is a non-GAAP measure. For additional information, including a reconciliation of Adjusted EBITDA to the most directly comparable measure presented in accordance with GAAP, see the explanation of non-GAAP measures and reconciliation tables at the end of this release. During the fourth quarter and year ended December 31, 2025, we recorded $8.5 million of acquired in-process research and development expense associated with upfront payments and related acquisition expenses from our acquisition of Melt Pharmaceuticals. This amount is included in GAAP operating expenses and net income figures and is not added back to our Adjusted EBITDA, consistent with our approach to non-GAAP measures. Conference Call and Webcast Harrow will host a conference call to discuss the results at 8:00 a.m. ET on Tuesday, March 3, 2026. Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year. To participate via telephone, please register in advance using this link . Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call. About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn . Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward--looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking- statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking- statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Contact: Mike Biega, VP of Investor Relations and Communications mbiega@harrowinc.com 617-913-8890 HARROW, INC. CONDENSED CONSOLIDATED BALANCE SHEETS December 31, 2025 December 31, 2024 ASSETS Cash and cash equivalents $ 72,927,000 $ 47,247,000 All other current assets 138,823,000 142,404,000 Total current assets 211,750,000 189,651,000 All other assets 187,732,000 199,320,000 TOTAL ASSETS $ 399,482,000 $ 388,971,000 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities $ 96,302,000 $ 91,343,000 Loans payable, net of unamortized debt discount 243,184,000 219,539,000 All other liabilities 7,905,000 8,792,000 TOTAL LIABILITIES 347,391,000 319,674,000 TOTAL STOCKHOLDERS' EQUITY 52,091,000 69,297,000 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 399,482,000 $ 388,971,000 HARROW, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended December 31, For the Year Ended December 31, 2025 2024 2025 2024 Total revenues $ 89,092,000 $ 66,831,000 $ 272,303,000 $ 199,614,000 Cost of sales (18,468,000 ) (14,135,000 ) (67,934,000 ) (49,245,000 ) Gross profit 70,624,000 52,696,000 204,369,000 150,369,000 Selling, general and administrative 43,310,000 34,789,000 152,914,000 129,064,000 Research and development 11,723,000 4,755,000 20,940,000 12,230,000 Impairment of long-lived assets - 253,000 - 253,000 Total operating expenses 55,033,000 39,797,000 173,854,000 141,547,000 Income from operations 15,591,000 12,899,000 30,515,000 8,822,000 Total other expense, net (5,194,000 ) (6,636,000 ) (31,883,000 ) (26,142,000 ) Income tax expense (3,771,000 ) 514,000 (3,771,000 ) (161,000 ) Net income (loss) $ 6,626,000 $ 6,777,000 $ (5,139,000 ) $ (17,481,000 ) Net income (loss) per share: Basic $ 0.18 $ 0.19 $ (0.14 ) $ (0.49 ) Diluted $ 0.17 $ 0.24 $ (0.14 ) $ (0.49 ) HARROW, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS For the Year Ended December 31, 2025 2024 Net cash provided by (used in): Operating activities $ 43,864,000 $ (22,202,000 ) Investing activities (5,460,000 ) (33,164,000 ) Financing activities (12,724,000 ) 28,528,000 Net change in cash and cash equivalents 25,680,000 (26,838,000 ) Cash and cash equivalents at beginning of the period 47,247,000 74,085,000 Cash and cash equivalents at end of the period $ 72,927,000 $ 47,247,000 Non-GAAP Financial Measures In addition to the Company’s results of operations determined in accordance with U.S. generally accepted accounting principles (GAAP), which are presented and discussed above, management also utilizes Adjusted EBITDA, an unaudited financial measure that is not calculated in accordance with GAAP, to evaluate the Company’s financial results and performance and to plan and forecast future periods. Adjusted EBITDA is considered a “non-GAAP” financial measure within the meaning of Regulation G promulgated by the SEC. Management believes that this non-GAAP financial measure reflects an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results, provides a more complete understanding of the Company’s results of operations and the factors and trends affecting its business. Management believes Adjusted EBITDA provides meaningful supplemental information regarding the Company’s performance because (i) it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making; (ii) it excludes the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company’s core operating performance and that may obscure trends in the Company’s core operating performance; and (iii) it is used by institutional investors and the analyst community to help analyze the Company’s results. However, Adjusted EBITDA, and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the Company and the way they are calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP financial measures used by other companies, including the Company’s competitors. Adjusted EBITDA The Company defines Adjusted EBITDA as net income (loss), excluding the effects of stock-based compensation and expenses, impairment of intangible assets, interest, taxes, depreciation, amortization, investment loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net income (loss). Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net income (loss) as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs. The following is a reconciliation of Adjusted EBITDA, a non-GAAP measure, to the most comparable GAAP measure, net income (loss), for the three months and year ended December 31, 2025 and for the same periods in 2024: HARROW, INC. RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA For the Three Months Ended December 31, For the Year Ended December 31, 2025 2024 2025 2024 GAAP net income (loss) $ 6,626,000 $ 6,777,000 $ (5,139,000 ) $ (17,481,000 ) Stock-based compensation and expenses 3,800,000 4,794,000 12,502,000 17,619,000 Impairment of intangible assets - 253,000 - 253,000 Interest expense, net 5,186,000 6,375,000 24,180,000 22,786,000 Income tax expense 3,771,000 (514,000 ) 3,771,000 161,000 Depreciation 464,000 468,000 1,915,000 1,850,000 Amortization of intangible assets 4,315,000 4,075,000 16,991,000 11,783,000 Investment loss, net - - - 3,171,000 Other expense, net - 261,000 7,703,000 185,000 Adjusted EBITDA $ 24,170,000 $ 22,489,000 $ 61,923,000 $ 40,327,000